Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, rando…

Share on facebook
Share on twitter
Share on linkedin

The increase in the proportion of patients who achieved an objective response from
the addition of taselisib to endocrine therapy in a neoadjuvant setting is consistent
with the clinical benefit observed in hormone receptor-positive, HER2-negative, metastatic
breast cancer.


Scroll to Top